Sionna Therapeutics (NASDAQ:SION) Director Sells $84,237.30 in Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Peter Thompson sold 1,890 shares of the firm’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $44.57, for a total value of $84,237.30. Following the sale, the director directly owned 3,559,765 shares in the company, valued at $158,658,726.05. This trade represents a 0.05% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Sionna Therapeutics Stock Up 2.4%

Shares of Sionna Therapeutics stock opened at $36.11 on Friday. Sionna Therapeutics, Inc. has a 52 week low of $7.26 and a 52 week high of $45.00. The firm’s 50 day moving average is $41.08 and its two-hundred day moving average is $32.95. The firm has a market capitalization of $1.61 billion and a P/E ratio of -7.41.

Sionna Therapeutics (NASDAQ:SION) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.06.

Hedge Funds Weigh In On Sionna Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in SION. ProShare Advisors LLC acquired a new position in Sionna Therapeutics in the 4th quarter valued at about $202,000. Jennison Associates LLC grew its stake in shares of Sionna Therapeutics by 11.8% in the 4th quarter. Jennison Associates LLC now owns 1,115,278 shares of the company’s stock valued at $45,883,000 after purchasing an additional 117,903 shares during the last quarter. UBS Group AG grew its stake in shares of Sionna Therapeutics by 91.1% in the 4th quarter. UBS Group AG now owns 89,177 shares of the company’s stock valued at $3,669,000 after purchasing an additional 42,511 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Sionna Therapeutics by 3.7% in the fourth quarter. Vanguard Group Inc. now owns 1,184,951 shares of the company’s stock valued at $48,749,000 after purchasing an additional 41,797 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of Sionna Therapeutics by 105.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,272 shares of the company’s stock worth $423,000 after purchasing an additional 5,272 shares during the last quarter.

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. Lifesci Capital started coverage on shares of Sionna Therapeutics in a research note on Tuesday, December 23rd. They issued an “outperform” rating and a $60.00 price objective for the company. Royal Bank Of Canada reissued an “underperform” rating and issued a $24.00 target price on shares of Sionna Therapeutics in a report on Monday, December 1st. Weiss Ratings restated a “sell (e+)” rating on shares of Sionna Therapeutics in a research note on Monday, December 29th. Raymond James Financial reaffirmed a “strong-buy” rating and set a $53.00 price target on shares of Sionna Therapeutics in a research report on Monday, January 5th. Finally, Wall Street Zen upgraded Sionna Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Sionna Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $45.43.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.